Completed PHASE4 INTERVENTIONAL 2-arm NCT01061060

The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients

The Effect of Prostaglandin I2 (Beraprost Na), Administered Orally for Eight Weeks, on the Endothelial Cell Functional Disorder in Type II Diabetes Mellitus Patients With Symptoms of a Minute Peripheral Blood Flow Disorder

Sponsor: Astellas Pharma Korea, Inc.

Conditions Peripheral Microvascular Symptoms Type 2 Diabetes Mellitus

Interventions Placebo Prostaglandin I2

Updated 6 times since 2017 Last updated: Feb 11, 2016 Started: Jan 31, 2010 Primary completion: Oct 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01061060, this PHASE4 trial focuses on Peripheral Microvascular Symptoms and Type 2 Diabetes Mellitus and remains completed. Sponsored by Astellas Pharma Korea, Inc., it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Korea, Inc.
Yonsei University

Data source: Yonsei University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea